AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s latest clinical study, titled ‘An Open-label, Fixed-sequence, Three-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and to Assess the Effect of Erythromycin on AZD5004 in Healthy Participants,’ aims to evaluate the interactions of AZD5004 with several commonly used drugs. The study’s primary objective is to understand how AZD5004 affects the pharmacokinetics of these drugs in healthy individuals, which is crucial for determining safe and effective dosage regimens.
The intervention being tested is AZD5004, a drug administered in combination with Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide, and Erythromycin. The purpose is to observe how AZD5004 influences the absorption, distribution, metabolism, and elimination of these medications.
This Phase I study is interventional, employing a non-randomized, factorial design without masking. It is structured into three independent parts, each focusing on different drug interactions, with the primary goal of treatment assessment.
The study began on May 6, 2025, with its primary completion and estimated overall completion dates yet to be announced. The last update was recorded on August 4, 2025. These dates are significant as they mark the progress and expected milestones of the study.
The update on this study could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if the results indicate a positive safety and efficacy profile for AZD5004. This development could also impact the competitive landscape, as successful outcomes may position AstraZeneca favorably against competitors in the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.